One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Improving Survival and Predicting Toxicity in Older Patients With DLBCL: A Delicate Balance
Sonali M. Smith, MD1
doi : 10.1200/JCO.21.00202
Journal of Clinical Oncology 39, no. 11 (April 10, 2021) 1193-1195.
Feeding the Controversy: When Pelvic Irradiation Improves Outcomes in High-Risk and Very High-Risk Prostate Cancer
Imraan Jan, DO1 and Rahul R. Parikh, MD1
doi : 10.1200/JCO.20.03636
Journal of Clinical Oncology 39, no. 11 (April 10, 2021) 1196-1202.
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older
Lucie Oberic, MD1; Frederic Peyrade, MD, PhD2; Mathieu Puyade, MD3; Christophe Bonnet, MD, PhD4; Peggy Dartigues-Cuillères, MD5; Bettina Fabiani, MD6; Philippe Ruminy, PhD7; Hervé Maisonneuve, MD8; Julie Abraham, MD9; Catherine Thieblemont, MD, PhD10; Pierre Feugier, MD, PhD11; Gilles Salles, MD, PhD12; Fontanet Bijou, MD13; Gian-Matteo Pica, MD14; Gandhi Damaj, MD, PhD15; Corinne Haioun, MD, PhD16; René-Olivier Casasnovas, MD17; Hassan Farhat, MD18; Ronan Le Calloch, MD19; Agathe Waultier-Rascalou, MD20; Sandra Malak, MD21; Jerome Paget, PhD22; Elodie Gat, PhD22; Hervé Tilly, MD, PhD23; and Fabrice Jardin, MD, PhD23
doi : 10.1200/JCO.20.02666
Journal of Clinical Oncology 39, no. 11 (April 10, 2021) 1203-1213.
The prognosis of elderly patients with diffuse large B-cell lymphoma (DLBCL) is worse than that of young patients. An attenuated dose of chemotherapy—cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-miniCHOP)—is a good compromise between efficacy and safety in very elderly patients. In combination with R-CHOP (R2-CHOP), lenalidomide has an acceptable level of toxicity and may mitigate the negative prognosis of the non–germinal center B-cell–like phenotype. The Lymphoma Study association conducted a multicentric, phase III, open-label, randomized trial to compare R-miniCHOP and R2-miniCHOP.
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi
Francesco Merli, MD1; Stefano Luminari, MD1,2; Alessandra Tucci, MD3; Annalisa Arcari, MD4; Luigi Rigacci, MD5; Eliza Hawkes, MD6; Carlos S. Chiattone, MD7,8; Federica Cavallo, MD9; Giuseppina Cabras, MD10; Isabel Alvarez, MD1; Alberto Fabbri, MD11; Alessandro Re, MD3; Benedetta Puccini, MD5; Allison Barraclough, MD12; Marcia Torresan Delamain, MD13; Simone Ferrero, MD9; Sara Veronica Usai, MD10; Angela Ferrari, MD1; Emanuele Cencini, MD11; Elsa Pennese, MD14; Vittorio Ruggero Zilioli, MD15; Dario Marino, MD16; Monica Balzarotti, MD17; Maria Christina Cox, MD18; Manuela Zanni, MD19; Alice Di Rocco, MD20; Arben Lleshi, MD21; Barbara Botto, MD22; Stefan Hohaus, MD23; Michele Merli, MD24; Roberto Sartori, MD25; Guido Gini, MD26; Luca Nassi, MD27; Gerardo Musuraca, MD28; Monica Tani, MD29; Chiara Bottelli, MD3; Sofia Kovalchuk, MD5; Francesca Re, MD30; Leonardo Flenghi, MD31; Annalia Molinari, MD32; Giuseppe Tarantini, MD33; Emanuela Chimienti, MD21; Luigi Marcheselli, MS34; Caterina Mammi, PhD35; and Michele Spina, MD21
doi : 10.1200/JCO.20.02465
Journal of Clinical Oncology 39, no. 11 (April 10, 2021) 1214-1222.
To prospectively validate the use of a simplified geriatric assessment (sGA) at diagnosis and to integrate it into a prognostic score for older patients with diffuse large B-cell lymphoma (DLBCL).
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes
Matteo Bersanelli, PhD1,2; Erica Travaglino , BSc3; Manja Meggendorfer, PhD4; Tommaso Matteuzzi, PhD1,2; Claudia Sala , PhD1,2; Ettore Mosca , PhD5; Chiara Chiereghin , PhD3; Noemi Di Nanni, PhD5; Matteo Gnocchi, MSc5; Matteo Zampini , PhD3; Marianna Rossi, MD3; Giulia Maggioni, MD3,6; Alberto Termanini , PhD3; Emanuele Angelucci, MD7; Massimo Bernardi , MD8; Lorenza Borin, MD9; Benedetto Bruno, MD10,11; Francesca Bonifazi, MD12; Valeria Santini , MD13; Andrea Bacigalupo , MD14; Maria Teresa Voso , MD15; Esther Oliva , MD16; Marta Riva, MD17; Marta Ubezio, MD3; Lucio Morabito , MD3; Alessia Campagna, MD3; Claudia Saitta, MSc18; Victor Savevski, MEng3; Enrico Giampieri , PhD2,19; Daniel Remondini , PhD1,2; Francesco Passamonti , MD20; Fabio Ciceri, MD8; Niccol? Bolli, MD21,22; Alessandro Rambaldi , MD23; Wolfgang Kern, MD4; Shahram Kordasti , MD24,25; Francesc Sole , PhD26; Laura Palomo , PhD26; Guillermo Sanz , MD27,28; Armando Santoro , MD3,6; Uwe Platzbecker , MD29; Pierre Fenaux, MD30; Luciano Milanesi , PhD5; Torsten Haferlach, MD4; Gastone Castellani , PhD2,19; and Matteo G. Della Porta , MD3,6
doi : 10.1200/JCO.20.01659
Journal of Clinical Oncology 39, no. 11 (April 10, 2021) 1223-1233.
Recurrently mutated genes and chromosomal abnormalities have been identified in myelodysplastic syndromes (MDS). We aim to integrate these genomic features into disease classification and prognostication.
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
Vedang Murthy, MD1; Priyamvada Maitre, MD1; Sadhana Kannan, MSc2; Gitanjali Panigrahi, MSc1; Rahul Krishnatry, MD1; Ganesh Bakshi, MCh3; Gagan Prakash, DNB3; Mahendra Pal, DNB3; Santosh Menon, MD4; Reena Phurailatpam, MSc5; Smruti Mokal, MSc2; Dipika Chaurasiya, BSc1; Palak Popat, DNB6; Nilesh Sable, MD6; Archi Agarwal, DNB7; Venkatesh Rangarajan, DNB7; Amit Joshi, DM8; Vanita Noronha, DM8; Kumar Prabhash, DM8; and Umesh Mahantshetty, MD1
doi : 10.1200/JCO.20.03282
Journal of Clinical Oncology 39, no. 11 (April 10, 2021) 1234-1242.
We report the clinical outcomes of a randomized trial comparing prophylactic whole-pelvic nodal radiotherapy to prostate-only radiotherapy (PORT) in high-risk prostate cancer.
Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas
Mary-Ann El Sharouni, MD1,2; Tasnia Ahmed, MSc1; Alexander H. R. Varey, PhD1,3,4; Sjoerd G. Elias, PhD5; Arjen J. Witkamp, MD6; Vigf?s Sigurdsson, MD2; Karijn P. M. Suijkerbuijk, MD7; Paul J. van Diest, MD8; Richard A. Scolyer, MD1,3,9; Carla H. van Gils, PhD5; John F. Thompson, MD1,3,10, Willeke A. M. Blokx, MD8; and Serigne N. Lo, MD1,3
doi : 10.1200/JCO.20.02446
Journal of Clinical Oncology 39, no. 11 (April 10, 2021) 1243-1252.
Although the prognosis of patients with thin primary cutaneous melanomas (T1, ? 1.0 mm) is generally excellent, some develop recurrence. We sought to develop and validate a model predicting recurrences in patients with thin melanomas.
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
Rafal Dziadziuszko, MD, PhD1; Matthew G. Krebs , MD, PhD2; Filippo De Braud, MD3,4; Salvatore Siena, MD3,5; Alexander Drilon , MD6; Robert C. Doebele, MD, PhD7; Manish R. Patel, DO8; Byoung Chul Cho , MD, PhD9; Stephen V. Liu , MD10; Myung-Ju Ahn, MD, PhD11; Chao-Hua Chiu, MD12; Anna F. Farago , MD, PhD13; Chia-Chi Lin , MD14; Christos S. Karapetis, MBBS, MMedSc15; Yu-Chung Li, MD16; Bann-mo Day, PhD17; David Chen, PharmD17; Timothy R. Wilson, PhD17; and Fabrice Barlesi , MD, PhD18,19
doi : 10.1200/JCO.20.03025
Journal of Clinical Oncology 39, no. 11 (April 10, 2021) 1253-1263.
Genetic rearrangements of the tyrosine receptor kinase ROS proto-oncogene 1 (ROS1) are oncogenic drivers in non-small-cell lung cancer (NSCLC). We report the results of an updated integrated analysis of three phase I or II clinical trials (ALKA-372-001, STARTRK-1, and STARTRK-2) of the ROS1 tyrosine kinase inhibitor, entrectinib, in ROS1 fusion–positive NSCLC.
High Prevalence of Weight Gain in Childhood Brain Tumor Survivors and Its Association With Hypothalamic-Pituitary Dysfunction
Jiska van Schaik, MSc1,2; Ichelle M. A. A. van Roessel, MSc1; Netteke A. Y. N. Schouten-van Meeteren, PhD2; Laura van Iersel, PhD1; Sarah C. Clement, PhD3; Annemieke M. Boot, PhD4; Hedi L. Claahsen-van der Grinten, PhD5; Marta Fiocco, PhD2,6; Geert O. Janssens, PhD2,7; Dannis G. van Vuurden, PhD2; Erna M. Michiels, PhD2; Sen K. S. Han, PhD2,8; Paul A. S. P. van Trotsenburg, MD, PhD9; Peter W. P. Vandertop, MD, PhD10; Leontien C. M. Kremer, MD, PhD2; and Hanneke M. van Santen, PhD1,2
doi : 10.1200/JCO.20.01765
Journal of Clinical Oncology 39, no. 11 (April 10, 2021) 1264-1273.
Childhood brain tumor survivors (CBTS) are at risk for developing obesity, which negatively influences cardiometabolic health. The prevalence of obesity in CBTS may have been overestimated in previous cohorts because of inclusion of children with craniopharyngioma. On the contrary, the degree of weight gain may have been underestimated because of exclusion of CBTS who experienced weight gain, but were neither overweight nor obese. Weight gain may be an indicator of underlying hypothalamic-pituitary (HP) dysfunction. We aimed to study prevalence of and risk factors for significant weight gain, overweight, or obesity, and its association with HP dysfunction in a national cohort of noncraniopharyngioma and nonpituitary CBTS.
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
Katherine S. Virgo , PhD, MBA1; R. Bryan Rumble, MSc2; Ronald de Wit, MD, PhD3; David S. Mendelson, MD4; Thomas J. Smith , MD5; Mary-Ellen Taplin, MD6; James L. Wade III , MD7; Charles L. Bennett , MD, PhD8; Howard I. Scher, MD9; Paul L. Nguyen, MD6; Martin Gleave, MD10; Scott C. Morgan , MD, MSc11; Andrew Loblaw, MD, MSc12; Sean Sachdev , MD13; David L. Graham , MD14; Neha Vapiwala, MD15; Amy M. Sion , PharmD16; Virgil H. Simons, MPA17; and James Talcott , MD, SM18
doi : 10.1200/JCO.20.03256
Journal of Clinical Oncology 39, no. 11 (April 10, 2021) 1274-1305.
Update all preceding ASCO guidelines on initial hormonal management of noncastrate advanced, recurrent, or metastatic prostate cancer.
Noncancer Deaths in the PETACC 6 Trial
Piotr Potemski, MD, PhD and Krzysztof Bujko, MD, PhD
doi : 10.1200/JCO.20.03091
Journal of Clinical Oncology 39, no. 11 (April 10, 2021) 1306-1306.
Reply to P. Potemski and K. Bujko
Hans-Joachim Schmoll , MD, Murielle E. Mauer, PhD, Sandrine Marreaud, PhD, and Alexander Stein , MD
doi : 10.1200/JCO.20.03687
Journal of Clinical Oncology 39, no. 11 (April 10, 2021) 1306-1308.
Erratum
doi : 10.1200/JCO.21.00642
Journal of Clinical Oncology 39, no. 11 (April 10, 2021) 1309-1309.
Erratum
doi : 10.1200/JCO.21.00602
Journal of Clinical Oncology 39, no. 11 (April 10, 2021) 1309-1309.
